netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Chapter Links...
 Details...
08.01.05  Expand sub section  Other antineoplastic drugs
Acalabrutinib (Calquence®)
View adult BNF View SPC online View SMC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
BlueTeq
  • 100mg capsules
  • Approved for treating chronic lymphocytic leukaemia in adults in line with NICE
 
Link  NICE TA689: Acalabrutinib for treating chronic lymphocytic leukaemia
 
Cytotoxic Drug Aflibercept (Zaltrap®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
 
Link  NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
Link  MHRA Drug Safety Update (April 2016): Aflibercept (Zaltrap▼): minimising the risk of osteonecrosis of the jaw
Link  MHRA Drug Safety Update (July 2020): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
 
AlectinibBlack Triangle (Alecensa®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
BlueTeq
  • 150mg capsules
  • Approved as an option for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) in adults in line with NICE 
 
Link  NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
 
Asciminib (Scemblix®)
View adult BNF View SPC online View SMC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
BlueTeq
  • 20mg and 40mg tablets
  • Approved as an option for treating chronic-phase Philadelphia chromosome-positive chronic myeloid leukaemia without a T315I mutation after 2 or more tyrosine kinase inhibitors in adults, in line with NICE
 
Link  NICE TA813: Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors
 
Cytotoxic Drug Atezolizumab
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
BlueTeq
  • 840mg/14ml & 1200mg/20m concentrate for solution for infusion (IV)
  • 1875mg/15ml solution for injection (S/C)
  • Approved for treating locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults who have had chemotherapy (and targeted treatment if they have an EGFR- or ALK‑positive tumour).  
  • Approved in combination with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (HCC) in adults who have not had previous systemic treatment in line with NICE
  • Approved for the treatment of advanced non-small-cell lung cancer in line with NICE
  • Approved for untreated PD-L1-positive locally advanced or metastatic urothelial cancer in adults when cisplatin-containing chemotherapy is unsuitable in line with NICE
  • Approved for for adjuvant treatment of resected non-small-cell lung cancer in adults in line with NICE
  • Approved with carboplatin and etoposide is recommended as an option for untreated extensive-stage small-cell lung cancer in adults in line with NICE
  • Approved with nab‑paclitaxel for triple-negative, unresectable, PD‑L1‑positive, locally advanced or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease in line with NICE
  • Approved for untreated PD-L1-positive locally advanced or metastatic urothelial cancer in adults when cisplatin-containing chemotherapy is unsuitable in line with NICE
 
Link  NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
Link  NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Link  NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
Link  NICE TA638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer
Link  NICE TA639: Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer
Link  NICE TA666: Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma
Link  NICE TA705: Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer
Link  NICE TA739: Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable
Link  NICE TA823: Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer
Link  MHRA Drug Safety Update (June 2021): Atezolizumab (Tecentriq▼) and other immune-stimulatory anti-cancer drugs: risk of severe cutaneous adverse reactions (SCARs)
 
Axicabtagene ciloleucel
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
  • 0.4 – 2 × 108 cells dispersion for infusion
 
Link  NICE TA872: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies
Link  NICE TA895: Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy
 
Brexucabtagene autoleucel (Tecartus®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund
NHS England
  • 0.4 – 2 × 108 cells dispersion for infusion
 
Link  NICE TA893: Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over
 
Cytotoxic Drug Carfilzomib (Kyprolis®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
BlueTeq
  • Approved for use in previously treated multiple myeloma in line with NICE and NHSE Commissioning Policy
  • Approved in combination with dexamethasone and lenalidomide for previously treated multiple myeloma in line with NICE

 

 
Link  NICE TA657: Carfilzomib for previously treated multiple myeloma (COVID-19)
Link  NICE TA695: Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma
Link  MHRA Drug Safety Update (Aug 2019): Carfilzomib (Kyprolis▼): reminder of risk of potentially fatal cardiac events
Link  MHRA Drug Safety Update (Dec 2019): Carfilzomib (Kyprolis▼): risk of reactivation of hepatitis B virus
 
CemiplimabBlack Triangle (Libtayo®)
View adult BNF View SPC online View SMC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
BlueTeq
  • Approved for treating metastatic or locally advanced cutaneous squamous cell carcinoma in adults in line with NICE
 
Link  NICE TA802: Cemiplimab for treating advanced cutaneous squamous cell carcinoma
 
Chlormethine Gel
View adult BNF View SPC online View childrens BNF
Formulary
Red
NHS England

160 micrograms/g gel

Approved for use in accordance with the following NICE TAs or if the indication is funded from the Cancer Drugs Fund:

Overview | Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma | Guidance | NICE

Commissioner: NHS England

Only to be used in line with a current chemotherapy protocol from the North of England Cancer Alliance in line with the appropriate Network Site Specific Group’s clinical guidelines or chemotherapy algorithm.

 
 
Crisantaspase (Erwinase)
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
 
Cytotoxic Drug Crizanlizumab (Adakveo®)
View adult BNF View SPC online View SMC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
BlueTeq
  • Approved preventing sickle cell crises in people aged 16 or over with sickle cell disease in line with NICE

 

 
Link  NICE TA743: Crizanlizumab for preventing sickle cell crises in sickle cell disease
 
Cytotoxic Drug Dacomitinib (Vizimpro®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
BlueTeq
  • Approved as an option for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in adults in line with NICE

 

 
Link  NICE TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
 
Cytotoxic Drug Daratumumab (Darzalex®)
View adult BNF View SPC online View SMC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
BlueTeq
  • Approved in combination with bortezomib, thalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable in line with NICE
  • Approved as an option for treating relapsed and refractory multiple myeloma in adults who have had a proteasome inhibitor and an immunomodulator, and whose disease progressed on the last treatment in line with NICE
  • Approved with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable in line with NICE and NHSE Specialised Commissioning guidance

 

 
Link  NICE TA763: Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable
Link  NICE TA783: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
Link  NICE TA897: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
Link  NICE TA917: Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable
Link  MHRA Drug Safety Update (Aug 2019): Daratumumab (Darzalex▼): risk of reactivation of hepatitis B virus
 
Cytotoxic Drug Dinutuximab beta (Qarziba®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
BlueTeq
  • 20mg/4.5mL concentrate for solution for infusion 
  • Approved for the treatment of high-risk neuroblastoma in people aged 12 months and over in line with NICE
 
Link  NICE TA 538: Dinutuximab beta for treating neuroblastoma
 
Dostarlimab  (Jemperli)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Vial: concentrate for infusion 500 mg/10 mL

 
Link  NICE TA 779: Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
 
 
Cytotoxic Drug DurvalumabBlack Triangle (Imfinzi®)
View adult BNF View SPC online View SMC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
  • Approved for locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation in adults in line with NICE
 
Link  NICE TA798: Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation
 
Entrectinib (Rozlytrek®)
View adult BNF View SPC online View SMC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
BlueTeq
  • Approved for ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults who have not had ROS1 inhibitors in line with NICE
 
Link  NICE TA643: Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer
Link  NICE TA644 Entrectinib for treating NTRK fusion-positive solid tumours
 
Cytotoxic Drug Eribulin (Halaven®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
  • Approved for the treatment of locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens  in accordance with NICE and NHS England Commissioning Policy
 
Link  NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
 
Fedratinib
View adult BNF View SPC online View childrens BNF
Formulary
Red

Capsule: 100 mg

 
Link  NICE TA 756: Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis
 
 
FostamatinibBlack Triangle
View adult BNF View SPC online View childrens BNF
Formulary
Red

100mg and 150mg film-coated tablets

Approved for use in accordance with the following NICE TAs or if the indication is funded from the Cancer Drugs Fund:

• NICE TA835: Fostamatinib for treating refractory chronic immune thrombocytopenia

Commissioner: NHS England

Only to be used in line with a current chemotherapy protocol from the North of England Cancer Alliance in line with the appropriate Network Site Specific Group’s clinical guidelines or chemotherapy algorithm

 
Link  NICE TA835: Fostamatinib for treating refractory chronic immune thrombocytopenia
 
Cytotoxic Drug Gemtuzumab ozogamicin (Mylotarg®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
BlueTeq
  •  Approved for untreated acute myeloid leukaemia in line with NICE
 
Link  NICE TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
 
Gilteritinib (Xospata®)
View adult BNF View SPC online View SMC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
BlueTeq
  • Approved for relapsed or refractory FLT3-mutation-positive acute myeloid leukaemia in adults in line with NICE
 
Link  NICE TA642: Gilteritinib for treating relapsed or refractory acute myeloid leukaemia
 
Glofitamab (Columvi®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
  • 2.5mg and 10mg concentrate for solution for infusion
  • Approved for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments in line with NICE and NHSE Specialised Commissioning guidance
 
Link  NICE TA927: Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments
 
Cytotoxic Drug Idelalisib
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
BlueTeq
  • Approved in combination with rituximab for the treatment of:
    • Untreated chronic lymphocytic leukaemia in adults with a 17p deletion or TP53 mutation; NICE or
    • Chronic lympocytic leukaemia in adults when the disease has been treated but has relapsed within 24 months NICE.

 

 
Link  NICE TA359: Chronic lymphocytic leukaemia - Idelalisib
Link  MHRA Drug Safety Update (May 2016): Idelalisib (Zydelig▼): interim measures following signal of serious infection and deaths related to infection found in clinical trials.
Link  MHRA Drug Safety Update (September 2016): Idelalisib (Zydelig▼): updated indications and advice on minimising the risk of infection  
 
Imlifidase (Idefirix®)
View adult BNF View SPC online View SMC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
  • 11mg powder for concentrate for solution for infusion
  • Approved for desensitisation treatment before kidney transplant in people with chronic kidney disease in line with NICE and NHSE Commissioning Policy
 
Link  NICE TA809: Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease
 
Cytotoxic Drug Inotuzumab ozogamicin (Besponsa®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

  • Approved for treating relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia in adults in line with NICE

 
Link  NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
 
IsatuximabBlack Triangle
View adult BNF View SPC online View childrens BNF
Formulary
Red

20mg/mL concentrate for solution for infusion.

Approved for use in accordance with the following NICE TAs or if the indication is funded from the Cancer Drugs Fund:

• NICE TA658: Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma

Not approved in accordance with the following NICE TAs:

• NICE TA727: Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)

Commissioner: NHS England

Only to be used in line with a current chemotherapy protocol from the North of England Cancer Alliance in line with the appropriate Network Site Specific Group’s clinical guidelines or chemotherapy algorithm.

 
Link  NICE TA658: Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma
 
IxazomibBlack Triangle
View adult BNF View SPC online View childrens BNF
Formulary
Red
  • Capsules: 2.3mg, 3mg, 4mg

 

 
Link  NICE TA870: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
 
LarotrectinibBlack Triangle
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England

20 mg/mL oral solution

 
Link  NICE TA630: Larotrectinib for treating NTRK fusion-positive solid tumours
 
LorlatinibBlack Triangle (Lorviqua®)
View adult BNF View SPC online View SMC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
BlueTeq
  • Approved for previously treated ALK-positive advanced non-small-cell lung cancer in adults in line with NICE
 
Link  NICE TA628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer
 
Lutetium (177Lu) oxodotreotideBlack Triangle
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
 
Cytotoxic Drug Midostaurin (Rydapt®)
View adult BNF View SPC online View SMC online View childrens BNF
Formulary
Red
NHS England
BlueTeq
  • Approved for the treatment of advanced systemic mastocytosis in line with NICE

 

 
Link  NICE TA523 Midostaurin for untreated acute myeloid leukaemia
Link  NICE TA728: Midostaurin for treating advanced systemic mastocytosis
 
Cytotoxic Drug Mogamulizumab  (Poteligeo®)
View adult BNF View SPC online View SMC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
BlueTeq
  • Approved for previously treated mycosis fungoides and Sézary syndrome in line with NICE

 

 
Link  NICE TA754: Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome
 
Cytotoxic Drug Neratinib (Nerlynx®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
BlueTeq
  • Approved for the treatment of early hormone receptor-positive HER2-positive breast cancer after adjuvant trastuzumab in line with NHS England Commissioning Policy and NICE
 
Link  NICE TA612: Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab
 
Niraparib (Zejula®)
View adult BNF View SPC online View SMC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
BlueTeq
  • Approved for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer in adults in line with NICE
 
Link  MHRA Drug Safety Update (Oct 2020): Niraparib (Zejula▼): reports of severe hypertension and posterior reversible encephalopathy syndrome (PRES), particularly in early treatment
Link  NICE TA673: Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
Link  NICE TA784: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
 
Cytotoxic Drug Nivolumab  (Opdivo®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
BlueTeq
  • For the treatment of locally advanced or metastatic squamous nonsmall cell lung cancer (NSCLC) after prior chemotherapy in adults.
  • Approved for the treatment of advanced (unresectable or metastatic) melanoma in adults in line with NICE.
  • Approved in combination with ipilimumab for treating advanced melanoma in line with NICE and NHS England Commissioning Policy (SSC1664)
  • Approved for the treatment of advanced renal cell carcinoma in adults in line with NICE and NHS England Commissioning Policy
  • Approved for the treatment of relapsed of refractory classical Hodgkin lymphoma in line with NICE and NHS England Commissioning Policy 
  • Approved for the treatment of  locally advanced or metastatic squamous non-small-cell lung cancer (NSCLC) in adults after chemotherapy in line with NICE
  • Approved for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease in adults
  • Approved for use in patients with previously untreated unresectable advanced or recurrent oesophageal cancer in line with NICE
  • Approved in combination ipilimumab for use in patients with previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency in line with NICE
  • Approved for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy in adults in line with NICE
  • Approved adjuvant treatment of completely resected oesophageal or gastro‑oesophageal junction cancer in adults who have residual disease after previous neoadjuvant chemoradiotherapy in line with NICE
  • Approved in combination with ipilimumab for untreated advanced renal cell carcinoma in line with NICE
  • Approved for adjuvant treatment of invasive urothelial cancer at high risk of recurrence in line with NICE
  • Approved with ipilimumab or untreated unresectable malignant pleural mesothelioma in adults in line with NICE
  • Approved for treating locally advanced or metastatic non-squamous non-small-cell lung cancer (NSCLC) in adults after chemotherapy in line with NICE
  • Approved (with fluoropyrimidine-based and platinum-based combination chemotherapy) for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma in adults whose tumours express PD‑L1 at a level of 1% or more.
  • Approved as an option for the neoadjuvant treatment of resectable (tumours at least 4 cm or node positive) non-small-cell lung cancer (NSCLC) in adults - in line with NICE TA876.
 
Link  MHRA Drug Safety Update (July 2017): Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection
Link  MHRA Drug Safety Update (Oct 2019): Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation
Link  NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
Link  NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Link  NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma
Link  NICE TA462 Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
Link  NICE TA530: Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy
Link  NICE TA655: Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy
Link  NICE TA684: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
Link  NICE TA707: Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer
Link  NICE TA713: Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy
Link  NICE TA716: Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
Link  NICE TA724: Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small- cell lung cancer
Link  NICE TA736: Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy
Link  NICE TA746: Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer
Link  NICE TA780: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
Link  NICE TA817: Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence
Link  NICE TA818: Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma
Link  NICE TA865: Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma
Link  NICE TA876: Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer
 
Cytotoxic Drug Olaparib  (Lynparza®)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England
BlueTeq
  • Approved for the maintenance treatment of BRCA 1 or 2 mutated, relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer in people whose relapsed disease has responded to platinum-based chemotherapy in line with NICE.
  • Approved for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer in adults with a BRCA1 or BRCA2 mutation in line with NICE
  • Approved for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy in adults in line with NICE
  • Approved for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer in adults in line with NICE
  • Approved as maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy in adults in line with NICE and NHSE Specialised Commissioning guidance
 
Link  NICE TA886: Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy
Link  NICE TA887: Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer
Link  NICE TA908: Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy
 
Pablociclib (Ibrance®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
 
Cytotoxic Drug Panobinostat
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
BlueTeq
  • Approved in combination with bortezomib and dexamethasone as an option for the treatment of multiple myeloma in line with NICE.

 

 
Link  NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
 
Cytotoxic Drug Pembrolizumab  (Keytruda®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
BlueTeq
  • Approved for the treatment of advanced melanoma after disease progression with ipilimumab in accordance with NICE.  
  • Approved for the treatment of advanced melanoma not previously treated with ipilimumab in accordance with NICE. 
  • Approved for treating PD-L1-positive non-small-cell lung cancer 
  • Approved for treating PD-L1-positive metastatic non-small-cell lung cancer 
  • Approved for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD L1 with a combined positive score (CPS) of 1 or more in line with NICE
  • Approved with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (NSCLC) in adults whose tumours have no epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-positive mutations.
  • Approved for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy in adults in line with NICE
  • Approved for untreated metastatic colorectal cancer with high microsatellite instability or mismarhc repair deficiency in line with NICE
  • Approved with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer in adults in line with NICE
  • Approved for adjuvant treatment of completely resected stage 3 melanoma in line with NICE
  • Approved in combination with carboplatin and paclitaxel for adults with untreated metastatic squamous non-small-cell lung cancer in line with NICE
  • Approved for treating relapsed or refractory classical Hodgkin lymphoma in people aged 3 and older who have had a stem cell transplant or at least 2 previous therapies in line with NICE
  • Approved with paclitaxel or nab‑paclitaxel for triple-negative, locally recurrent unresectable or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease in line with NICE
  • Approved for adjuvant treatment of renal cell carcinoma in adults in line with NICE
  • Approved for the adjuvant treatment of resected stage 2B and 2C melanoma in people 12 years and over in line with NICE
  • Approved with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (NSCLC) in adults whose tumours have no epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-positive mutations in line with NICE
  • Approved plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer in adults in line with NICE
  • Approved with lenvatinib for previously treated advanced or recurrent endometrial cancer in line with NICE and NHSE Specialised Commissioning guidance
  • Approved for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency in adults in line with NICE and NHSE Specialised Commissioning guidance
 
Link  NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
Link  NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Link  NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
Link  NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Link  NICE TA661: Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma
Link  NICE TA683: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
Link  NICE TA692: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Link  NICE TA709: Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
Link  NICE TA737: Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer
Link  NICE TA766: Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma
Link  NICE TA770: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
Link  NICE TA772: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies
Link  NICE TA801: Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer
Link  NICE TA830: Pembrolizumab for adjuvant treatment of renal cell carcinoma
Link  NICE TA837: Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma
Link  NICE TA885: Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer
Link  NICE TA904: Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer
Link  NICE TA914: Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency
Link  MHRA Drug Safety Update (July 2017): Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection
 
Polatuzumab vedotinBlack Triangle (Polivy®)
View adult BNF View SPC online View SMC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
BlueTeq
  • Approved with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma in adults who cannot have a haematopoietic stem cell transplant in line with NICE
  • Approved with rituximab, cyclophosphamide, doxorubicin and prednisolone (R‑CHP) for untreated diffuse large B-cell lymphoma (DLBCL) in adults - in line with NICE TA874.
 
Link  NICE TA649: Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma
Link  NICE TA874: Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma
 
PomalidomideBlack Triangle
View adult BNF View SPC online View childrens BNF
Formulary
Red

Commissioner: NHS England

Only to be used in line with a current chemotherapy protocol from the North of England Cancer Alliance in line with the appropriate Network Site Specific Group’s clinical guidelines or chemotherapy algorithm

 

 

 
Link  NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
 
Ramucirumab (Cyramza®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
 
Link   NICE TA378: Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy
Link  NICE TA403: Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer
Link  MHRA Drug Safety Update (July 2020): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
 
Rucaparib
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund

Film coated tablets: 200mg, 250mg, 300mg

 
Link  NICE TA 611: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
 
Link  MHRA Drug Safety Update (Sep 2022) Rucaparib (Rubraca▼): withdrawal of third-line treatment indication
 
Sacituzumab govitecan (Trodelvy®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
  • 180mg powder for solution for infusion
 
Link  NICE TA819: Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies
 
SelpercatinibBlack Triangle
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
  • 40mg and 80mg capsules
  • Approved for advanced thyroid cancer with RET alterations in people 12 years and older in line with NICE
  • Approved for untreated RET fusion-positive advanced non-small-cell lung cancer in adults in line with NICE
 
Link  NICE TA742: Selpercatinib for treating advanced thyroid cancer with RET alterations
Link  NICE TA760: Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer
Link  NICE TA911: Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer
 
SelumetinibBlack Triangle (Koselugo®)
View adult BNF View SPC online View SMC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
BlueTeq
  • 10mg and 35mg hard capsules
  • Approved treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over in line with NICE
 
Link  NICE HST20: Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over
 
SotorasibBlack Triangle (Lumykras)
View adult BNF View SPC online View childrens BNF
Formulary
Red

Tablets: 120 mg

 
Link  NICE TA 781: Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer
 
 
Cytotoxic Drug Talimogene laherparepvec
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England

  • Approved for the treatment of unresectable metastatic melanoma in line with NICE and NHS England Commissioning Policy (SSC1679).

 
Link  NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma
 
TisagenlecleucelBlack Triangle
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
  • Indicated for treating 'paediatric and young adult patients up to 25 years of age with B‑cell acute lymphoblastic leukaemia that is refractory, in relapse post‑transplant or in second or later relapse as per NICE

     

  • NICE has recommended tisagenlecleucel for use within the Cancer Drugs Fund for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic therapies. 
Link  NICE TA 554: Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years
Link  NICE TA 567: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies
 
 
TivozanibBlack Triangle (Fotivda®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
  • Capsules: 890 mg and 1340 mg
 
Link  NICE TA512: Tivozanib for treating advanced renal cell carcinoma
Link  MHRA Drug Safety Updates (July 2020) Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
 
Trastuzumab deruxtecanBlack Triangle (Enhertu)
View adult BNF View SPC online View childrens BNF
Formulary
Red
NHS England

Vial: powder for concentrate for infusion, 100 mg

 
Link  NICE TA704: Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies
Link  NICE TA862: HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments
 
Cytotoxic Drug Venetoclax (Venclyxto®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
BlueTeq
  • Approved in combination with rituximab for treating chronic lymphocytic leukaemia in adults who have had at least 1 previous therapy in line with NICE
  • Approved in combination with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable in line with NICE
  • Approved in combination with low dose cytarabine for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable in line with NICE.
  • Approved for the treatment of chronic lymphocytic leukaemia in adults:
    • with a 17p deletion or TP53 mutation and when a B‑cell receptor pathway inhibitor is unsuitable, or whose disease has progressed after a B‑cell receptor pathway inhibitor or
    • without a 17p deletion or TP53 mutation, and whose disease has progressed after both chemo‑immunotherapy and a B‑cell receptor pathway inhibitor in line with NICE

 

 
Link  NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
Link  NICE TA663 Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia
Link  NICE TA765: Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable
Link  NICE TA787: Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable
Link  NICE TA796: Venetoclax for treating chronic lymphocytic leukaemia
Link  MHRA Drug Safety Update (Dec 2021): Venetoclax (Venclyxto▼): updated recommendations on tumour lysis syndrome (TLS)
 
Picibanil
View adult BNF View SPC online View childrens BNF
Unlicensed Drug Unlicensed
Red
 
 
Streptozocin
View adult BNF View SPC online View childrens BNF
Unlicensed Drug Unlicensed
Red
  • Named patient supply only.
 
 
08.01.05  Expand sub section  Amsacrine
Cytotoxic Drug Amsacrine
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
 
08.01.05  Expand sub section  CDK inhibitors
08.01.05  Expand sub section  Arsenic trioxide
Cytotoxic Drug Arsenic Trioxide
View adult BNF View SPC online View childrens BNF
Formulary
Red
  • NECDAG approved relapsed or refractory acute promyelocytic leukaemia (APL).
 
Link  NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia
 
08.01.05  Expand sub section  Bevacizumab to top
Bevacizumab (Avastin®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
 
Link  NICE TA284:Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Link  NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab
Link  NICE TA353: Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal)
Link  MHRA Drug Safety Update (January 2011): Bevacizumab and sunitinib: risk of osteonecrosis of the jaw
Link  MHRA Drug Safety Update (July 2020): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
 
08.01.05  Expand sub section  Bexarotene
Bexarotene (Targretin®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
 
08.01.05  Expand sub section  Bortezomib
Cytotoxic Drug Bortezomib
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
  • Approved for:
    • Relapsed multiple myeloma in line with in line with NICE.
    • Combination with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma in line with NICE. 
    • Induction therapy for multiple myeloma in line with NICE.
    • Treatment of adults with mantle cell lymphoma that has not been treated before, if haemotopoietic stem cell transplantation is not suitable, in line with NICE.
 
Link  NICE TA129: Multiple myeloma - bortezomib
Link  NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
Link  NICE TA311: Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation
Link  NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
 
08.01.05  Expand sub section  Brentuximab vedotin
Cytotoxic Drug Brentuximab vedotin (Adcetris®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
  • 50mg powder for concentrate for solution for infusion
  • Approved for the treatment of relapsed or refractory systemic anaplastic large cell lymphoma in line with NICE and NHS England Commissioning Policy.
  • Approved for the treatment of CD30-positive Hodgkin lymphoma in patients:
    • if they have already had autologous stem cell transplant
    • if they have already had at least 2 previous therapies when autologous stem cell transplant or multi-agent chemotherapy are not suitable. CDF
  • Approved for the treatment of CD30-positive cutaneous T-cell lymphoma in line with NICE
  • Approved in combination with cyclophosphamide, doxorubicin and prednisone for untreated systmic anaplastic large cell lymphoma in adults in line with NICE

 

 
Link  NICE TA478 Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Link  NICE TA524 Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Link  NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
Link  NICE TA641: Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma
 
08.01.05  Expand sub section  Cetuximab
Cetuximab
View adult BNF View SPC online View childrens BNF
Formulary
Red
  • Approved for the first-line treatment of metastatic colorectal cancer in combination with FOLFOX in line with NICE (monotherapy or combination chemotherapy is not recommended for the treatment of people with metastatic colorectal cancer that has progressed after first-line chemotherapy -  as per NICE). 
  • NECDAG approved for K-RAS wild type metastatic colorectal cancer; second line use in combination with chemotherapy in patients that have progressed on previous chemotherapy; third line use as a single agent in patients who have failed oxaliplatin- and irinotecan based therapy and who are intolerant to irinotecan. 
  • Approved for locally advanced squamous cell carcinoma of the head and neck in line with NICE. 
  • Approved for previously untreated metastatic colorectal cancer in line with NICE.
  • Approved for the treatment of metastatic and/or recurrent squamous cell carcinoma of the head and neck (oral cavity only) in line with NICE and NHS England Commissioning Policy
  • Note: cetuximab is not approved in combination with platinum-based chemotherapy for recurrent and/or metastatic squamous cell cancer of the head and neck as per NICE.
 
Link  NICE TA145: Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck
Link  NICE TA242: Cetuximab for the treatment of metastatic colorectal cancer after first-line chemotherapy: monotherapy or combination chemotherapy
Link  NICE TA439 Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Link  NICE TA473 Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (oral cavity)
Link  MHRA Drug Safety Update (Feb 2014): Cetuximab: new safety information available
Link  MHRA Drug Safety Update (May 2012): Epidermal growth factor receptor (EGFR) inhibitors: serious cases of keratitis and ulcerative keratitis
 
08.01.05  Expand sub section  Dacarbazine and Temozolomide to top
Cytotoxic Drug Dacarbazine
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
 
Cytotoxic Drug Temozolomide
View adult BNF View SPC online View childrens BNF
Formulary
Red
  • Approved for the treatment of recurrent malignant glioma in line with NICE.
  • Approved for newly diagnosed glioblastoma multiforme (GBM) in line with NICE.
 
Link  NICE TA121: Glioma (newly diagnosed and high grade)
Link  NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
 
08.01.05  Expand sub section  Erlotinib
Erlotinib
View adult BNF View SPC online View childrens BNF
Formulary
Red
  • Also approved for second line use, as an alternative to docetaxel, in NSCLC in line with NICE.
  • Monotherapy not approved for maintenance after platinum chemotherapy in advanced or metastatic NSCLC NICE.
  • Approved for the treatment of locally advanced or metastatic nonsmall-cell lung cancer that has already been treated with non-targetted chemotherapy because of delayed confirmation of epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation status if; their cancer tests positive for EGFR-TK mutation; it is not know if the cancer is EGFR-TK mutation- positive because of problems with the test, and the cancer is very likely to be EGFR-TK mutation-positive and it responds to the first 2 cycles of treatment with erlotinib - in line with NICE.
 
Link  NICE TA227: Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer
Link  NICE TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
Link  NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Link  Roche Healthcare Professional Letter (January 2016): Tarceva (erlotinib)
Link  MHRA Drug Safety Update (May 2012): Epidermal growth factor receptor (EGFR) inhibitors: serious cases of keratitis and ulcerative keratitis
 
08.01.05  Expand sub section  Hydroxycarbamide
Cytotoxic Drug Hydroxycarbamide
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
 
08.01.05  Expand sub section  Imatinab
08.01.05  Expand sub section  Ipilimumab
Cytotoxic Drug Ipilimumab (Yervoy®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
BlueTeq
  • Approved for previously treated advanced melanoma in line with NICE.
  • Approved for previously untreated advanced melanoma in line with NICE.
  • Approved in combination with nivolumab for untreated renal cell carcinoma in line with NICE.
 
Link  NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Link  NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
Link  NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
Link  NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Link  NICE TA780: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
Link  MHRA Drug Safety Update (Jan 2019): Ipilimumab (Yervoy): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation
 
08.01.05  Expand sub section  Mitotane to top
Mitotane
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
 
08.01.05  Expand sub section  Panitumumab
Panitumumab (Vectibix®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

  • Approved for previously untreated metastatic colorectal cancer in line with NICE.

 
Link  NICE TA439 Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Link  MHRA Drug Safety Update (May 2010): Panitumumab (Vectibix): serious hypersensitivity reactions
Link  MHRA Drug Safety Update (May 2012): Epidermal growth factor receptor (EGFR) inhibitors: serious cases of keratitis and ulcerative keratitis
Link  MHRA Drug Safety Update (September 2012): Panitumumab (Vectibix): risk of necrotising fasciitis
Link  MHRA Drug Safety Update (September 2013): Panitumumab: treatment of metastatic colorectal cancer
 
08.01.05  Expand sub section  Pentostatin
Cytotoxic Drug Pentostatin (Nipent®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
 
08.01.05  Expand sub section  Platinum compounds
Cytotoxic Drug Carboplatin
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
 
Cytotoxic Drug Cisplatin
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
 
Cytotoxic Drug Oxaliplatin
View adult BNF View SPC online View childrens BNF
Formulary
Red
  • Approved for Dukes C colon cancer in combination with 5-fluorouracil
    and folinic acid in line with NICE.
  • Approved for advanced and metastatic colorectal cancer in line with NICE.
 
Link  NICE TA100: Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer
 
08.01.05  Expand sub section  Porfimer sodium and temoporfin
Porfimer Sodium (Photofrin ®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
 
08.01.05  Expand sub section  Procarbazine to top
Cytotoxic Drug Procarbazine
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
 
08.01.05  Expand sub section  Protein kinase inhibitors
Afatinib
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England

  • Approved as a possible treatment for adults with locally advanced or metastatic non-small-cell lung cancer if their cancer tests positive for the epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation and they have not had an EGFR-TK inhibitor before NICE and additional NHS England criteria.

 
Link  NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
 
Axitinib  (Inlyta®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
  • Approved as treatment for adults with advanced renal cell carcinoma when tyrosine kinase inhibitors or cytokines have not worked in line with NICE.

 

 
Link  MHRA Drug Safety Update (July 2020): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
Link  NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
Link  NICE TA645: Avelumab with axitinib for untreated advanced renal cell carcinoma
 
Bosutinib (Bosulif®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
  • Approved as an option for the treatment of chronic, accelerated blast phase Philidephia chromosome positive chronic myeloid leukaemia in adults when they have previously had 1 or more tyrosine kinase inhibitor and imatinib, nilotinib and dasatanib are not appropriate in line with NICE.
 
Link  NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia
Link  MHRA Drug Safety Update (May 2016): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation
 
Cytotoxic Drug Brigatinib (Alunbrig®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
BlueTeq
  • Approved for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) in adults who have already had crizotinib in line with NICE.
  • Approved for treating ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor in line with NICE
 
Link  NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
Link  NICE TA670: Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor
 
Cabozantinib (Cometriq®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
  • Approved for use in the treatment of renal cell carcinoma in line with NICE and NHS England Commissioning Policy
  • Approved for the treatment of medullary thyroid cancer in line with NICE and NHS England Commissioning Policy
  • Approved for use in untreated advanced renal cell carcinoma in line with NICE and NHS England Commissioning Policy
 
Link   NICE TA849: Cabozantinib for previously treated advanced hepatocellular carcinoma
Link  NICE TA 542: Cabozantinib for untreated advanced renal cell carcinoma
Link  NICE TA463 Cabozantinib for previously treated advanced renal cell carcinoma
Link  NICE TA516: Cabozantinib for treating medullary thyroid cancer
Link  MHRA Drug Safety Update (July 2020): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
 
Ceritinib
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
  • Approved for use in previously treated anaplastic lymphoma kinase positive non-small-cell-lung cancer in line with NICE and NHS England Commissioning Policy.
  • Approved for untreated ALK-positive non-small-cell lung cancer in line with NICE and NHS England Commissioning Policy
 
Link  NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Link  NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
 
Crizotinib
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
  • Approved in accordance with NICE and NHS England Commissioning Policy.
 
Link  NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Link  NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Link  NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
Link  MHRA Drug Safety Update (Nov 2015): Crizotinib (Xalkori▼): risk of cardiac failure
 
Dabrafenib  (Tafinlar®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
NHS England
BlueTeq
  • Approved for the treatment of unresectable or metastatic BRAF V600 mutation-positive melanoma in line with NICE 
  • Approved for the treatment of BRAF-mutated anaplastic thyroid cancer (ATC) in line with NHSE Specialised Commissioning Policy
  • Approved with trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer in adults in line with NICE

 

 
Link  NICE TA321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma
Link  NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Link  NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
Link  NICE TA898: Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer
 
Dasatinib (Sprycel®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
  • Approved for use in accordance with NICE and NHS EnglandCommissioning Policy
 
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Link  MHRA Drug Safety Update (May 2016): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation
 
Cytotoxic Drug Encorafenib (Braftovi®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England

  • Approved in combination with binimetinib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma in adults in line with NICE

  • Approved in combination with cetuximab (Erbitux) for treating BRAF V600E mutation-positive metastatic colorectal cancer in adults who have had previous systemic treatment

 
Link  NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
Link  NICE TA668: Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer
 
Everolimus (Afinitor®, Votubia®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
  • 2.5mg, 5mg & 10mg tablets (Votubia®)
    • Approved for the treatment of angiomyolipomas associated with tuberous sclerosis in accordnace with NHS England Commissioning Policy.
    • Approved for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in accordnace line with NHS England Commissioning Policy.
  • 5mg & 10mg tablets (Afinitor®)
    • Approved, in combination with exemestane, for the treatment of advanced human epidermal growth factor receptor 2 (HER2)-negative, hormone-receptor-positive breast cancer in postmenopausal women in accordance with NICE.
    • Approved for the treatment of advanced breast cancer after endocrine therapy in line with NICE.
    • Approved for the treatment of advanced renal cell carcinoma after previous treatment in line with NICE.
    • Approved for the treatment of unresectable or metastatic neuroendocrine tumours in people with progressive disease in line with NICE and NHS England Commissioning Policy
 
Link  Clinical Commissioning Policy Statement: Everolimus (Votubia®) for treatment of angiomyolipomas associated with tuberous sclerosis
Link  Clinical Commissioning Policy: Everolimus for subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex
Link  NICE TA348: Everolimus for preventing organ rejection in liver transplantation
Link  NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Link  NICE TA432: Everolimus (Afinitor) for advanced renal cell carcinoma after previous treatment
Link  NICE TA449 Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Link  NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Link  NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
Link  NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
 
Gefitinib
View adult BNF View SPC online View childrens BNF
Formulary
Red
  • Approved for first line use in locally advanced or metastatic NSCLC in line with NICE.
 
Link  NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
Link  NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Link  MHRA Drug Safety Update (May 2012): Epidermal growth factor receptor (EGFR) inhibitors: serious cases of keratitis and ulcerative keratitis
 
Ibrutinib (Imbruvica®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
  • Approved for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation in line with NICE and NHS Commissioning Policy.
  • Approved for treating relapsed or refractory mantle cell lymphoma in line with NICE and NHS England Commissioning Policy if:
    • they have had only 1 previous line of therapy
  • Approved for untreated chronic lymphocytic leukaemia in line with NICE
 
Link  NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
Link  NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
Link  NICE TA795: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
Link  NICE TA891: Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia
Link  MHRA Drug Safety Update (August 2017): Ibrutinib (Imbruvica▼): reports of ventricular tachyarrhythmia; risk of hepatitis B reactivation and of opportunistic infections
 
Imatinib
View adult BNF View SPC online View childrens BNF
Formulary
Red
NHS England
  • Approved for the first-line management of people with KIT (CD117)- positive unresectable and/or KIT (CD117)-positive metastatic gastrointestinal stromal tumours (GISTs) in line with NICE. 
  • Approved for the adjuvant treatment of gastrointestinal stromal tumours (GISTs) after surgery when there is a high risk relapse of tumour NICE. 
  • Approved for Philadelphia-chromosome-positive CML in the accelerated phase or with blast crisis in line with NICE.
  • A standard-dose imatinib is recommended as an option for the first-line treatment of adults with chronic phase Philadelphia-chromosomepositive CML in line with NICE.
 
Link  NICE TA209: Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours
Link  NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Link  NICE TA70: Guidance on the use of imatinib for chronic myeloid leukaemia
Link  NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
Link  MHRA Drug Safety Update (May 2016): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation
 
Lapatinib (Tyverb®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
Link  NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
 
Lenvatinib (Kisplyx®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
  • 4mg & 10mg capsules
  • Approved with everolimus for previously treated advanced renal cell carcinoma in line with NICE
  • Approved to the treatment of differentiated thyroid cancer after radioactive iodine in line with NICE
  • Approved for untreated advanced hepatocellular carcinoma in line with NICE
 
Link  NICE TA 535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
Link  NICE TA 551: Lenvatinib for untreated advanced hepatocellular carcinoma
Link  NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
Link  MHRA Drug Safety Update (July 2020): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
 
Mobocertinib
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
 
Link  NICE TA855: Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy
 
Nilotinib (Tasigna®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
NHS England
  • Approved for the first-line treatment of adults with chronic phase Philadelphia-chromosome-positive CML in line with NICE and NHS Commissioning Policy
 
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Link  MHRA Drug Safety Update (May 2016): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation
 
Nintedanib
View adult BNF View SPC online View childrens BNF
Formulary
Red
  • Approved for the treatment of locally advanced, metastatic or locally recurrent non-small-cell lung cancer who have previously been treated been with first-line chemotherapy in accordance with NICE.
  • Approved for treating idiopathic pumonary fibrosis in line with NICE
 
Link  NICE TA347: Recurrent non-small-cell lung cancer
Link  NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis
Link  NICE TA747 Nintedanib for treating progressive fibrosing interstitial lung diseases
Link  NICE TA864: Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted
Link  MHRA Drug Safety Update (July 2020): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
 
Pazopanib (Votrient®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
  • Approved for advanced renal cell carcinoma in line with NICE
 
Link  NICE TA215: Pazopanib in renal cell cancer
Link  MHRA Drug Safety Update (July 2020): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
 
Pemigatinib (Pemaryze®)
View adult BNF View SPC online View SMC online View childrens BNF
Formulary
Red
  • 4.5mg, 9mg and 13.5mg tablets
  • Approved for the treatment of relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement in line with NICE

 

 
Link  NICE TA722: Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement
 
Ponatinib (Iclusig®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
  • 15mg, 30mg & 45mg film-coated tablets
  • Approved for the treatment of chronic myeloid leukaemia and acute lymphoblastic leukaemia in line with NICE and NHS England Commissioning Policy
 
Link  NICE TA451 Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
Link  MHRA Drug Safety Update (July 2020): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
Link  MHRA Drug Safety Update (October 2018): Ponatinib (Iclusig▼): reports of posterior reversible encephalopathy syndrome
Link  MHRA Drug Safety Update (April 2017): Ponatinib  (Iclusig▼): risk of vascular occlusive events—updated advice on possible dose reduction
Link  MHRA Drug Safety Update (May 2016): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation
 
Cytotoxic Drug Regorafenib (Stivarga® )
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
BlueTeq
  • 40mg tablets
  • Approved for treating unresectable or metastatic gastrointestinal stromal tumours in adults whose disease has progressed on, or who are intolerant to, prior treatment with imatinib and sunitinib in line with NICE and NHS England Commissioning Policy.
  • Approved for treating advanced hepatocellular carcinoma in adults who have had sorafenib in line with NICE
  • Approved as an option for metastatic colorectal cancer in adults who have had previous treatment (including fluoropyrimidine-based chemotherapy, anti‑VEGF therapy and anti‑EGFR therapy) or when these treatments are unsuitable - in line with NICE.
 
Link  NICE TA 488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
Link  NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma
Link  NICE TA866: Regorafenib for previously treated metastatic colorectal cancer
Link  MHRA Drug Safety Update (July 2020): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
 
Ruxolitinib
View adult BNF View SPC online View childrens BNF
Formulary
Red
  • Approved for the treatment of disease-related splenomegaly or symptoms in adults with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemiaa myelofibrosis, only in people with intermediate-2 or high-risk disease in line with NICE.
  • Approved for treating polycythaemia vera in line with NICE and NHSE Specialised Commissioning guidance

 

 
Link  NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
Link  NICE TA921: Ruxolitinib for treating polycythaemia vera
 
Sorafenib (Nexavar®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
  • 200mg tablets
  • Approved for treatment of advanced hepatocellular carcinoma only for people with Child-Pugh grade A liver impairment in line with NICE and NHS Commissioning Policy.
  • Approved for the treatment of differentiated thyroid cancer after radioactive iodine in line with NICE.
 
Link  NICE TA 535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
Link  NICE TA474 Sorafenib for treating advanced hepatocellular carcinoma
Link  MHRA Drug Safety Update (July 2020): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
 
Sunitinib  (Sutent®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
  • Approved for gastrointestinal stromal tumours (GISTs) in line with NICE.
  • Approved for advanced and/or metastatic renal cell carcinoma in line with NICE.
  • Sunitinib not approved for second line use in advanced and/or metastatic renal cell carcinoma NICE.
  • Approved for the treatment of unresectable or metastatic neuroendocrine tumours in people with progressive disease in line with NICE and NHS England Commissioning Policy
 
Link  NICE TA169: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma
Link  NICE TA179: Sunitinib for the treatment of gastrointestinal stromal tumours
Link  NICE TA449 Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Link  MHRA Drug Safety Update (January 2011): Bevacizumab and sunitinib: risk of osteonecrosis of the jaw
Link  MHRA Drug Safety Update (July 2020): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
 
Cytotoxic Drug Temsirolimus (Torisel®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
 
 
Trametinib
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
  • Approved in combination with dabrafenib for the treatment of unresectable or metastatic melanoma in line with NICE and NHS England Commissioning Policy.
  • Approved for the treatment of BRAF-mutated anaplastic thyroid cancer (ATC) in line with NHSE Specialised Commissioning Policy



 

 
Link  NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Link  NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
Link  MHRA Drug Safety Update (March 2016) Trametinib (Mekinist▼): risk of gastrointestinal perforation and colitis
 
Cytotoxic Drug Tucatinib (Tukysa®)
View adult BNF View SPC online View SMC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
  • Approved in combination with trastuzumab and capecitabine for HER2‑positive locally advanced or metastatic breast cancer in adults after 2 or more anti‑HER2 treatment therapies in line with NICE
 
Link  NICE TA786: Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies
 
Vemurafenib
View adult BNF View SPC online View childrens BNF
Formulary
Red
  • Approved melanoma (BRAF V600 mutation positive, unresectable metastatic) in line with NICE.
 
Link  NICE TA269: Vemurafenib for treating malignant melanoma
Link  NICE TA414: Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
 
Cytotoxic Drug Zanubrutinib (Brukinsa 80mg capsules®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
  • Capsule, 80mg
 
Link  NICE TA833: Zanubrutinib for treating Waldenstrom’s macroglobulinaemia
 
08.01.05  Expand sub section  Taxanes
Cytotoxic Drug Cabazitaxel
View adult BNF View SPC online View childrens BNF
Formulary
Red
  • Approved for the treatment of hormone relapsed metastatic prostate cancer treated with with docetaxel in line with NICE.
 
Link  MHRA Drug Safety Update (December 2014) Cabazitaxel (Jevtana▼): risk of medication error resulting in overdose
Link  NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
 
Cytotoxic Drug Docetaxel
View adult BNF View SPC online View childrens BNF
Formulary
Red
  • Approved for early node-positive breast cancer in line with NICE. 
  • Approved for hormone refractory metastatic prostate cancer in line with NICE.
 
Link  NICE NG101: Early and locally advanced breast cancer: diagnosis and management
Link  NICE TA101: Docetaxel for the treatment of hormone-refractory metastatic prostate cancer
 
Cytotoxic Drug Paclitaxel
View adult BNF View SPC online View childrens BNF
Formulary
Red
  • The following formulations are approved:
  • 30mg in 5ml, 100mg in 16.7ml, and 150mg in 25ml concentrate for preparing IV infusion.
  • Approved for the treatment of recurrent ovarian cancer in line with NICE.
 
Link  MHRA Drug Safety Update (Jan 2022): Paclitaxel formulations (conventional and nab-paclitaxel): caution required due to potential for medication error
Link  NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Link  NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer
 
Cytotoxic Drug Paclitaxel - Albumin Bound Formulation (Abraxane®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
  • Note: Abraxane® 5mg in 1ml powder for suspension for infusion is restricted for use within its current license for metastatic breast cancer patients who cannot tolerate standard taxanes. 
  • Approved in combination with a platinum-based compound or platinum-based therapy alone (cisplatin or carboplatin) for first line therapy in ovarian cancer in line with NICE.
  • Approved in combination with a platinum-based drug (carboplatin or cisplatin) for second-line (or subsequent) therapy in ovarian cancer in line with NICE
  • Approved metastatic breast cancer in line with NICE.
  • Abraxane is not recommended for the adjuvant treatment of women with early node-positive breast cancer NICE.
  • Approved in combination with gemcitabine for untreated metastatic pancreatic cancer in line with NICE and NHS England Commissioning Policy as of 5th December 2017
 
Link  NICE TA476 Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
Link  MHRA Drug Safety Update (Jan 2022): Paclitaxel formulations (conventional and nab-paclitaxel): caution required due to potential for medication error
 
08.01.05  Expand sub section  Topoisomerase I inhibitors
Cytotoxic Drug Irinotecan Hydrochloride
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
 
Cytotoxic Drug Topotecan
View adult BNF View SPC online View childrens BNF
Formulary
Red
  • Approved for relapsed NSCLC in line with NICE.
  • Approved for recurrent or stage IVB cervical cancer in line with NICE.
  • Approved for second-line (or subsequent) treatment in advanced ovarian cancer in line with NICE.
  • Approved for the treatment of recurrent ovarian cancer in line with NICE.
 
Link  NICE TA183: Topotecan for the treatment of recurrent and stage IVB cervical cancer
Link  NICE TA184: Topotecan for the treatment of relapsed small-cell lung cancer
Link  NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
 
08.01.05  Expand sub section  Trabectedin
Cytotoxic Drug Trabectedin
View adult BNF View SPC online View childrens BNF
Formulary
Red

Approved for the treatment of recurrent ovarian cancer in line with NICE.

 
Link  NICE TA185: Soft tissue sarcoma - trabectedin
Link  NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
 
08.01.05  Expand sub section  Trastuzumab to top
Pertuzumab (Perjeta®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

  • Approved for the neoadjuvant treatment of HER2-positive breast cancer in line with NICE and NHS Commissioning Policy

  • Approved with trastuzumab and docetaxel for treating HER2-positive breast cancer in line with NICE and NHS Commissioning Policy

  • Approved for adjuvant treatment of HER2-positive early stage breast cancer in line with NICE

 
Link  NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
Link  NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Link  NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
 
Trastuzumab
View adult BNF View SPC online View childrens BNF
Formulary
Red
  • Approved for metastatic or locally advanced inoperable gastric cancers in line with NICE.
  • Approved for early stage HER2-positive breast cancer in line with NICE.
  • Approved for advanced HER2-positive breast cancer in line with NICE.
  • Note: trastuzumab is not recommended in combination with an aromatase inhibitor for the first-line treatment in postmenopausal women with metastatic hormonereceptor- positive breast cancer that overexpresses HER2 - in line with NICE.
  • Trastuzumab 600mg subcutaneous injection is approved by NHS England for HER2-positive breast cancer in line with NECN guidance.
 
Link  NICE NG101: Early and locally advanced breast cancer: diagnosis and management
Link  NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Link  NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Link  NICE TA34: Breast cancer - trastuzumab
 
Cytotoxic Drug Trastuzumab emtansine (Kadcyla®)
(S/C injection)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
  • 100mg & 160mg powder for concentrate for solution for infusion
  • Approved for the treatment of HER2-positive advanced breast cancer after trastuzumab and a taxane in line with NICE and NHS England Commissioning Policy
  • Approved for human epidermal growth factor receptor 2 (HER2)‑positive early breast cancer in adults who have residual invasive disease in the breast or lymph nodes after neoadjuvant taxane-based and HER2‑targeted therapy in line with NICE
 
Link  NICE TA458 Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
Link  NICE TA632: Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer
 
08.01.05  Expand sub section  Tretinoin
Tretinoin
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
 
08.01.05  Expand sub section  Vismodegib
 ....
 Non Formulary Items
Mosunetuzumab  (Lunsumio®)

View adult BNF View SPC online View childrens BNF
Non Formulary
Not Recomended
  • 1mg/1ml and 30mg/30ml concentrate for solution for infusion
Link  NICE TA892: Mosunetuzumab for treating relapsed or refractory follicular lymphoma
Ripretinib  (Qinlock® )

View adult BNF View SPC online View childrens BNF
Non Formulary
Not Recomended
  • 50mg tablet
Link  NICE TA881: Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments
Tafasitamab  (Minjuvi® )

View adult BNF View SPC online View childrens BNF
Non Formulary
Not Recomended
  • 200mg powder for concentrate for solution for infusion
Link  NICE TA883: Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

Drugs for hospital use only. The responsibility for initiation and monitoring treatment should rest with an appropriate hospital clinician and the drug should be supplied through the hospital throughout the duration of treatment. In some very exceptional circumstances (e.g. due to distance from the hospital, storage, supply or mobility/transport problems) it may be appropriate for the GP to be asked to prescribe a Red drug. This should be negotiated on an individual patient basis and should only be done with the GP’s prior informed agreement where the roles of the GP and hospital services are clearly defined and agreed. The GP should not feel under pressure to prescribe in these circumstances. For all RED drugs automatically added to the formulary in response to a positive NICE TA: Prescribers need to ensure that local Trust new drug governance procedures and pharmacy processes are followed before any prescribing.  

Amber

Drugs initiated by hospital specialist, but where continuing treatment by GPs may be appropriate under a shared care arrangement. The specialist should send the GP a copy of the shared care agreement to sign. The GP should sign the shared care agreement, or indicate they do not want to be part of such an agreement, and return a copy back to the specialist. Shared care guidelines are available or are being developed for most of the drugs listed as Amber. If no shared care guideline is available, the hospital specialist should provide the patient’s GP with sufficient information and support to allow treatment to be continued and managed safely in primary care.  

Green plus

Drugs normally recommended or initiated by a specialist (hospital or GP with an extended role https://www.rcgp.org.uk/gpwer), but can be safely maintained in primary care with very little or no monitoring required. In some cases there may be a further restriction for use outlined - these will be defined in each case. Provision of additional information, or an information leaflet, may be appropriate in some cases to facilitate continuing treatment by GPs.  

Green

Drugs where prescribing by GPs is appropriate. Can be initiated and prescribed in all care settings, and if appropriate, discontinued without recourse to secondary care.  

Black

NOT APPROVED: Drugs that have been considered by NTAG or the NENC ICB Medicines Subcommittee (or other approved body) and are not approved for prescribing within the North East and North Cumbria.   

Brown

UNDER REVIEW: drugs whose current formulary status or RAG status is currently under review.  

Not Recomended

NOT REVIEWED: Drugs that haven not been reviewed yet. This usually means that an application is in progress. These drugs are not normally considered appropriate for prescribing in the North East and North Cumbria until such time that a decision is taken on their formulary status.  

netFormulary